Ayman Abd Elhamid Shouman
Institute of Ophthalmology, Cairo-Egypt
Title: Incidence of diabetes mellitus (DM) is increasing worldwide
Biography
Biography: Ayman Abd Elhamid Shouman
Abstract
The duration of diabetes and glycaemic control is collective risk factors for severity and progression of diabetic retinopathy. Diabetic macular edema (DME) emerges as one of the leading causes of blindness. The incidence of diabetes and its retinal complications is increasing in a rapid pace especially in the gulf region. The treatment of DME has evolved from focal and grid laser photocoagulation as the gold standard of therapy for DME, as stated in the Early Treatment of Diabetic Retinopathy Study (ETDRS), yet, the evolvement of new modalities specially the intravitreal injection changed the paradigm of treatment of DME. New therapies has developed with proven efficacy like vascular endothelial growth factor inhibitors (VEGF) agents like Bevacizumab and Ranibizumab, VEGF and placental growth factor inhibitor like Aflibercept, Corticosteroid materials like Triamcinolone Acetonide, Dexamethasone and Fluocinolone Acetonide. A high volume of studies to support such modalities have been conducted including RISE and RIDE, RESOLVE , DRCR, RRESTORE, RETAIN, RELIGHT, VIVID, VISTA, CHAMPLAIN, ETC…. A review of the different results of these trials with different case reviews with the different modalities of treatment is to be presented and discussed.